Combination/sequential therapy with ETV, Peg-IFN alpha-2b and GMCSF enhanced HBsAg loss and appearance of HBsAb in NA suppressed CHB patients (the Anchor A study): an interim analysis
单位：[1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Hubei, Peoples R China华中科技大学同济医学院附属同济医院[2]Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China[3]Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Peoples R China[4]Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China[5]China Med Univ, Shengjing Hosp, Shenyang, Liaoning, Peoples R China中国医科大学盛京医院[6]Xiamen Amoytop Biotech Co Ltd, Xiamen, Peoples R China
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Hubei, Peoples R China
推荐引用方式(GB/T 7714)：
Han Meifang,Wu Di,Tan Deming,et al.Combination/sequential therapy with ETV, Peg-IFN alpha-2b and GMCSF enhanced HBsAg loss and appearance of HBsAb in NA suppressed CHB patients (the Anchor A study): an interim analysis[J].HEPATOLOGY.2017,66:13A-13A.
APA：
Han, Meifang,Wu, Di,Tan, Deming,Chen, Yongping,Chen, Xinyue...&Ning, Qin.(2017).Combination/sequential therapy with ETV, Peg-IFN alpha-2b and GMCSF enhanced HBsAg loss and appearance of HBsAb in NA suppressed CHB patients (the Anchor A study): an interim analysis.HEPATOLOGY,66,
MLA：
Han, Meifang,et al."Combination/sequential therapy with ETV, Peg-IFN alpha-2b and GMCSF enhanced HBsAg loss and appearance of HBsAb in NA suppressed CHB patients (the Anchor A study): an interim analysis".HEPATOLOGY 66.(2017):13A-13A
医学